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Background: Feline infectious peritonitis (FIP) is a fatal disease caused by feline coronavirus (FCoV). FCoVs are
divided into two serotypes with markedly different infection rates among cat populations around the world. A
baculovirus-expressed type-specific domain of the spike proteins of FCoV was used to survey the infection of the
two viruses over the past eight years in Taiwan.
Results: An immunofluorescence assay based on cells infected with the recombinant viruses that was capable of
distinguishing between the two types of viral infection was established. A total of 833 cases from a teaching
hospital was surveyed for prevalence of different FCoV infections. Infection of the type I FCoV was dominant, with a
seropositive rate of 70.4%, whereas 3.5% of cats were infected with the type II FCoV. In most cases, results derived
from serotyping and genotyping were highly agreeable. However, 16.7% (4/24) FIP cats and 9.8% (6/61) clinically
healthy cats were found to possess antibodies against both viruses. Moreover, most of the cats (84.6%, 22/26)
infected with a genotypic untypable virus bearing a type I FCoV antibody.
Conclusion: A relatively simple serotyping method to distinguish between two types of FCoV infection was
developed. Based on this method, two types of FCoV infection in Taiwan was first carried out. Type I FCoV was
found to be predominant compared with type II virus. Results derived from serotyping and genotyping support our
current understanding of evolution of disease-related FCoV and transmission of FIP.
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Feline coronavirus (FCoV), a common pathogen in cats,
is an enveloped, positive-sense, single-stranded RNA
virus. Together with canine coronavirus (CCoV), trans-
missible gastroenteritis virus (TGEV), porcine respira-
tory coronavirus and human coronavirus 229E (HCoV
229E), FCoV is classified into the genus Alphacorona-
virus [1]. Two pathotypes of FCoV have been well dem-
onstrated, i.e., feline enteric coronavirus (FECV) and feline
infectious peritonitis (FIP) virus (FIPV). The former causes* Correspondence: linglingchueh@ntu.edu.tw; chwan@ntu.edu.tw
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unless otherwise stated.mild enteric infections, and the latter causes a fatal
immune-mediated disease known as FIP [2].
Infection with coronavirus is determined by the inter-
action between the receptor binding domain of its spike
(S) protein and corresponding receptors on target cells.
S protein is the main determinant of cell tropism and of
the induction of neutralizing antibodies [3]. FCoVs can
be divided into two serotypes, types I and II, which differ
in the neutralizing antibody reaction and have distinct S
protein sequences [4]. These two types of FCoV differ in
growth characteristics in vitro. Type II FCoV is antigeni-
cally related to CCoV and TGEV [5]. The receptor usage
of the two types of FCoV is different [6]. Feline amino-
peptidase N was identified as a receptor for type II
FCoV, but not for type I FCoV [7]. The main receptortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dritic cell-specific intercellular adhesion molecule-grabbing
nonintegrin serves as a coreceptor for both type I and II
FCoV [8]. Both types of FCoV can infect domestic and wild
Felidae and cause FIP [2]. Seroprevalence studies for the
detection of the two types of FCoV infection have been
performed using various methods, and type I FCoV was
found to be predominant in the field, with a seropositive
rate of 83-98%, whereas the type II virus accounted for
only less than 10% of infections [9-11].
In this study, a type-specific partial S protein-based
immunofluorescence assay (IFA) was established to dis-
tinguish between the two serotypes of FCoV. The sero-
prevalence of FCoV in Taiwan was determined, and the




For the cultivation, purification and titration of recom-
binant baculovirus (r-virus), Spodoptera frugiperda-9
(Sf-9) cells were used in this study. The Sf-9 cells were
cultured in suspension at 27°C at densities ranging
from 0.5-2 × 106 cells/ml in HyQ SFX-Insect Media
(HyClone, Logan, UT, USA) containing 5% (v/v) fetal
bovine serum (FBS) (PAA Laboratories GmbH, Pasching,
Austria) and 10 μg/ml gentamicin.
Felis catus whole fetus-4 (Fcwf-4) cells were used for
the propagation of the type II FCoV strain NTU156 [12]
and maintained in Dulbecco’s modified Eagle’s medium
(Gibco, Grand Island, USA) supplemented with 10%
FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin
in 5% CO2 at 37°C.
Detection and genotyping of FCoV
Several samples were collected from the cats enrolled in
this study, including whole blood, plasma, swab samples
(rectal, nasal, oral and conjunctival swabs), body effu-
sions and internal organ samples, and were screened for
FCoV by reverse transcription-nested polymerase chain
reaction (RT-nPCR) [13]. FCoV-positive samples were
subsequently subjected to genotyping of the virus ac-
cording to the procedures reported by Addie et al. [14].
Clinical samples
To further characterize the correlation between the sero-
type of the infection and FIP, plasma samples from 43
pathologically confirmed, naturally occurring FIP cases
and 30 suspected FIP cases, which were FCoV RT-nPCR
positive in effusions with/without an IFA signal present
in macrophages [15], were further tested. Moreover, to
evaluate the seroprevalence of different types of FCoV
infection in Taiwan, plasma samples from 760 clinically
healthy cats were collected around the island of Taiwanfrom 1996–2013. All samples were stored at −20°C until
analysis. An ethical approval was not required as this
study was performed retrospectively and samples of dis-
eased animals were routinely submitted to the veterinary
diagnostic laboratory.
Detection of anti-FCoV antibody
For the screening of anti-FCoV antibody-positive sam-
ples, a type II FCoV-based IFA was used in the present
study. Fcwf-4 cells seeded in a 96-well plate were in-
fected with the type II FCoV strain NTU156 at a multi-
plicity of infection (MOI) of 0.01 and incubated for
18 hours. Once each well contained 30% infected cells
and 70% uninfected cells as an internal negative control,
the infected cells were fixed with cold 50/50 acetone/
methanol (v/v) for ten minutes. A plasma sample diluted
1:40 with PBS was transferred to the well and allowed to
incubate for 60 minutes at room temperature. Subse-
quently, the cells were washed 5 times with PBS, and
fluorescein isothiocyanate (FITC)-conjugated goat anti-
cat IgG (1:1000 dilution) was added to each well for a
60-minute incubation at room temperature. When syn-
cytial cells, which are a typical cytopathic effect (CPE) of
FCoV infection, showed fluorescent signals that were inter-
preted as positive, the cat was considered to be infected
with FCoV. Positive samples were further serotyped.
Amplification, cloning and expression of type-specific
S genes
Because S protein is the key determinant of the discrim-
ination of serotypes, a region specific to the two types of
FCoV was chosen for analysis. The type I FCoV strain
NTU2 (GenBank: DQ160294) and the type II FCoV
strain NTU156 (GenBank: GQ152141) were employed
in this study. Two pairs of primers based on the RBD re-
gion of the S gene, with the restriction site EcoR1, Kpn1
or BamH1, were designed (FCoV-I pRBD F: 5’-gaattcat
gttttactctgctagtatgctt-3’ and FCoV-I pRBD R: 5’-ggtacctt
aacccagctgtgcctttg-3’; FCoV-II pRBD F: 5’-ggatccatgcctgt
agcctcgagtgacg-3’ and FCoV-II pRBD R: 5’-ggtaccttagtg
aggaccactattatcagac-3’) and used to amplify the targeted
region of the S gene. This region was 510 and 513 nucle-
otides in length for type I and II FCoV, respectively. The
amplified products were cloned into the pFastBac™ HT
vector using the Bac-to-Bac Baculovirus Expression Sys-
tem (Invitrogen srl, Milan, Italy) following the manu-
facturer’s instructions. The FCoV-I pRBD-bacmid and
FCoV-II pRBD-bacmid were used to transfect Sf-9 cells
to obtain r-viruses (rFCoV-I and rFCoV-II) containing
an N-terminal 6× histidine tag.
Confirmation of recombinant proteins
Sf-9 cells were infected with rFCoV-I or rFCoV-II at different
MOI values, and cell pellets from different post-infection
Table 1 Prevalence of FCoV serotypes I and II in cats with
different disease statuses in Taiwan
Status Serotype n (%) Total
I II I/II Untypable
FIP 29 (67.4) 3 (7.0) 11 (25.6) 0 (0) 43
FIP-suspected 24 (80.0) 2 (6.7) 3 (10.0) 1 (3.3) 30
Non-FIP 149 (69.7) 5 (2.3) 37 (17.3) 23 (10.7) 214
Total 202 (70.4) 10 (3.5) 51 (17.8) 24 (8.3) 287
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expressed recombinant proteins were resolved by SDS-
PAGE and transferred to PVDF membranes. The mem-
branes were blocked using 5% (w/v) non-fat dry milk
for two hours at room temperature, followed by incu-
bation with an anti-histidine mouse monoclonal antibody
(mAb) (Invitrogen srl, Milan, Italy) at room temperature.
After washes in PBS-Tween 20, each membrane was incu-
bated with horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG antibody (Jackson ImmunoRe-
search Laboratories, PA, USA). The membranes were
developed with 3,3’,5,5’-tetramethylbenzidine (TMB) sub-
strate (Kirkegaard & Perry Laboratories, MD, USA).
Serotyping
To differentiate the serotypes of infection, a novel type-
specific IFA using rFCoV-I- or rFCoV-II -infected Sf-9
cells was established. Sf-9 cells seeded in a 96-well plate
were infected with either rFCoV-I or rFCoV-II at an
MOI of 0.5. After 72 hours of incubation, the infected
cells were fixed with cold acetone/methanol. Two-fold-
diluted plasma samples (from 1:50 to 1:1600) from cats
with FIP cats were transferred into the wells (rFCoV-I-
or and rFCoV-II -infected Sf-9 cells or mock infection)
and incubated for 60 minutes at room temperature. After
washing 5 times with PBS, 1000-fold-diluted FITC-
conjugated goat anti-cat IgG was added to each well
for 60 minutes at room temperature. FCoV-positive
sera collected from cats without FIP were diluted 1:100
and applied to the IFA system as above for serotyping
analysis. Two polyclonal antisera (VMRD, Pullman, WA,
USA) against type I and II FCoV were used as referenced
positive-control sera. Two sera from specific pathogen-
free (SPF) cats were used as negative-control sera. The
serotype of each FCoV infection was identified based on
rFCoV-I- or rFCoV-II-infected Sf-9 cells (rRBD-1 and
rRBD-II) showing a fluorescent signal after IFA staining
with 200-fold-diluted or higher plasma samples from cats
with FIP and 100-fold-diluted samples from healthy cats.
Neutralization test (NT)
To further compare the assay established in this study to
a gold standard method, plasma samples from FIP con-
firmed animals were examined by both NT test and the
type-specific IFA. Heat inactivated plasma samples were
diluted 10 and 100 fold followed by a two fold serial di-
lution up to 1600 fold. Subsequently, diluted sample
were mixed with an equal volume of a type II FCoV
strain NTU156 containing 100 PFU/50 μl and incubated
at 37°C for 1 h. Each mixture was then inoculated onto
Fcwf-4 cells monolayer in a 96 well microplate at 37°C
for 3 days. The reciprocal of the highest dilution of anti-
body that completely inhibited viral CPE formation was
expressed as the virus-neutralizing titer.Results
Prevalence of FCoV in Taiwan
All of the samples from the 43 confirmed FIP cases and 30
suspected FIP cases were FCoV seropositive. In addition to
the cats with FIP, a total of 760 clinically healthy cats col-
lected from 26 veterinary hospitals in 6 cities in Taiwan
over 8 years were enrolled in this study, 28.2% (214/760) of
which were positive for FCoV. The overall prevalence of
FCoV in Taiwan was 34.5% (287/833) (Table 1).
Amplification of S region based on RBD of type I and II
FCoV for type-specific protein expression
To distinguish between the serotypes of FCoV infection,
a novel type-specific IFA was established. To express the
protein fragment that is antigenically distinct between
type I and II FCoV, the type-specific region of the S
gene, based on the putative RBD of type II FCoV and
the corresponding region of type I FCoV, was selected.
The expressed regions were located from amino acids
no. 523 to no. 692 and no. 508 to no. 678 of the S pro-
teins of type I and II FCoV, respectively (Figure 1a). The
partial S genes of different types of FCoV were amplified,
directionally cloned into the pFastBac™ HT vector and
used to generate r-viruses, i.e., rFCoV-I and rFCoV-II.
Recombinant proteins with the expected size (approxi-
mately 23 kDa for type I and type II FCoV) were identi-
fied (Figure 1b).
Establishment and confirmation of type-specific IFA
The specificity of the type-specific IFA was verified using
plasma samples from the confirmed type I or II FCoV-
infected cats or from SPF cats. Both recombinant pro-
teins could be detected by the anti-histidine mAb, with a
positive signal located in the cytoplasm. In contrast, no
fluorescent signal was observed while using sera from
the SPF cats (Figure 2). The plasma from type I FCoV-
infected cats could specifically react with rRBD-I, but
not with rRBD-II, and vice versa. While using the plasma
samples from dually FCoV-infected cats with FIP, positive
signals could be observed for both types of r-RBD
(Figure 2). Based on these data, the specificity of both
recombinant proteins was confirmed. To further valid-
ate the assay, the serotyping result derived from type-
specific IFA was compared to a gold standard, NT.
Figure 1 Amplification and expression of the type-specific S region of type I and II FCoV. (a) The alignment of the amino acid sequences
of the putative RBD of S protein from type II FCoV and type I FCoV with the sequences from prototypic viral strains. The boxed nucleotides
represent N-linked glycosylation sites. GenBank accession number: FCoV NTU2 (GenBank: DQ160294), FCoV KU-2 (GenBank: AB086881), FCoV
UCD1 (GenBank: AB088222), FCoV Black (GenBank: EU186072), FCoV C1Je (GenBank: DQ848678), FCoV RM (GenBank: FJ938051), FCoV UU-2 (GenBank:
FJ938060), FCoV NTU156 (GenBank: GQ152141), FCoV 79–1146 (GenBank: DQ010921), FCoV 79–1683 (GenBank: JN634064), FCoV DF-2 (GenBank:
JQ408981), CCoV NTU336 (GenBank: GQ477367), CCoV CB05 (GenBank: DQ112226), CCoV 1–71 (GenBank: JQ404409) and TGEV Purdue (GenBank:
DQ811789). (b) Sf-9 cells were infected with two r-viruses (rFCoV-I and rFCoV-II) at different MOI values, and the cells were harvested at different
times post-infection. The putative RBD of S proteins (23 kDa in size) from type I and type II FCoV were confirmed by Western blotting using
an anti-histidine mAb.
Figure 2 Establishment and confirmation of the type-specific IFA. Sera from confirmed type I and/or II FCoV-infected cats with FIP, with type
I or II FCoV antisera or SPF cat serum as a reference, were applied to the IFA to characterize its specificity.
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FIP-1 As I (400) ≤10
FIP-2 As I (800) 10
FIP-3 As I (800) ≤10
FIP-4 As I (800)
FIP-5 B, R I (≥1600)
FIP-6 Lu I (400)
FIP-7 B, R I (800) ≤10
FIP-8 R I (800)
FIP-9 B I (800)
FIP-10 R I (400)
FIP-11 Pl I (400) 10
FIP-12 R, Br I (800) ≤10
FIP-13 R I (400) 10
FIP-14 Lu I (400)
FIP-15 As I (≥1600) ≤10
FIP-16 As I (200)
FIP-17 As I (400) 10
FIP-18 R I (400)/II (400)
FIP-19 As, R I (400)/II (400)
FIP-20 As I (≥1600)/II (400)
FIP-21 As, B, R II (≥1600)
FIP-22 Br II (≥1600) 400
FIP-23 Pl, Li, Ki II (≥1600) ≥1600
FIP-24 As, CSF, Ki I (≥1600)/II (≥1600) 800
FIP-25 I (≥1600) 10
FIP-26 I (400) ≤10
FIP-27 I (400) 10
FIP-28 I (800) ≤10
FIP-29 I (200)/II (400) ≥1600
FIP-30 I (800)/II (≥1600) ≥1600
FIP-31 I (400) ≤10
FIP-32 I (400) ≤10
FIP-33 I (800) ≤10
FIP-34 I (≥1600) 10
FIP-35 I (800) ≤10
FIP-36 I (400) ≤10
a: R, Rectal swabs; As, Ascites; Pl, Pleural effusions; B, Blood; CSF, Cerebrospinal
fluid; Li, Liver; Lu, Lung; Ki, Kidney; Br, Brain.
b: NT titer against a type II FIPV.
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against rRBD-II (≥400×) were found to possess a rela-
tively high NT titer (≥800×) against type II FCoV, indi-
cating a type II FIPV infection (5/5). On the other hand,
samples bearing antibody solely against rRBD-I (200 × −
1600×) showed barely detectable NT titer (≤10×) against
type II virus, indicating a type I FIPV infection (19/19)
(Table 2). The results show that serotypes determined by
the type-specific IFA test are highly agreeable with NT
test.
Association between FCoV genotype and serotype
Among seropositive cats, 70.4% (202/287) of cats had
antibodies specific to rRBD-I, whereas 3.5% (10/287) had
antibodies to rRBD-II, and 17.8% (51/287) reacted to
both types (Table 1). Infection with serotype I FCoV ap-
peared to be dominant in both the FIP and the non-FIP
groups (Table 1).
To evaluate the correlation between the serotype and
the genotype of the infection, plasma samples collected
from type I or II FCoV-infected cats with FIP were ana-
lyzed. In comparison of results derived from serotyping
and genotyping, the serotype of FCoV was found highly
agree with the genotype in most cases. For the cats with
type I FIP, most (17/20, 85%) had antibodies specific to
rRBD-I, except for three cats (FIP-18, FIP-19 and FIP-20)
(Table 2). Of the solely type II-infected cats with FIP, four
cats (FIP-21 to FIP-24) had titers specifically against
rRBD-II, but only one of these cats (FIP-24) possessed
antibodies against rRBD-I as well (Table 2).
Of the cats without FIP with type I FCoV detected by
RT-nPCR, 78.1% (25/32) had antibodies against r-RBD-I,
and 9.4% (3/32) were positive for antibodies against both
types. Additionally, the serotypes of four samples failed
to be identified. Moreover, three plasma samples col-
lected from healthy cats with type II FCoV detected in
fecal samples were used for serotyping [16]. All three
samples were FCoV seropositive, but only one was iden-
tified as infected by both types of FCoV. Of those cats
infected with the FCoVs that failed to be genotyped,
84.6% (22/26) possessed antibodies against type I FCoV
(Table 3).
Discussion
In this study, an FCoV type-specific, recombinant protein-
based IFA was established. The expressed recombinant
RBD region of the type II FCoV S protein, bearing one-
tenth of the authentic S protein critical in both virus
neutralization and cell attachment, is highly conserved
among FCoV, TGEV and CCoV [17]. The alignment of
the amino acid sequences of this region revealed relative
conservation among prototypic viral strains within the
same serotype (i.e., 86.8-95.4% and 91.4-98.3% of type
I and II FCoV, respectively) but were distinct betweendifferent serotypes (20.7-23.0%) (Figure 1a). As the
expressed partial S proteins contained four N-linked
glycosylation sites for both type I (551-NVT-553, 559-
NDT-561, 591-NGS-593 and 596-NVT-598) and type
Table 3 Correlation between serotype and genotype in FCoV
antibody-positive animals without FIP
RT-nPCR Genotype Serotype n (%) Total
I II I/II Negative
Positive I 25 (78.1) 0 (0) 3 (9.4) 4 (12.5) 32
II 0 (0) 0 (0) 1 (33.3) 2 (66.7) 3
UT 22 (84.6) 1 (3.8) 2 (7.7) 1 (3.8) 26
NA 23 (56.1) 1 (2.4) 13 (31.7) 4 (9.7) 41
Negative 24 (75) 1 (3.1) 3 (9.4) 4 (12.5) 32
NA 55 (68.8) 2 (2.5) 15 (18.7) 8 (10) 80
Total 149 (69.7) 5 (2.3) 37 (17.3) 23 (10.7) 214
UT: Untypable.
NA: Not available.
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NNT-568) FCoV (Figure 1a), the baculovirus expres-
sion system was chosen to provide post-translational
modification and complex folding, including glycosyla-
tion [18,19]. A similar strategy was applied to severe
acute respiratory syndrome (SARS)-CoV, and the re-
combinant RBD maintained authentic antigenicity that
induced a strong RBD-specific antibody response [20].
In addition, baculovirus-expressed, truncated SARS-
CoV S protein-based IFAs were found to be highly sen-
sitive and specific compared with conventional whole
virus-based IFAs [21,22].
Based on different testing methods, the prevalence
of FCoV in field cats varies among countries, e.g., 50%
in Switzerland [10], 34% in Australia [23], 22% in
Japan [11] and 13.7% in Korea [24]. In the present study,
FCoV-specific antibodies detected by IFA based on pro-
teins derived from a local FCoV isolate revealed a sero-
prevalence of 34.5%. Previous studies revealed that >80%
of seropositive cats are suspected to be infected with
type I FCoV [9-11]. In the present study, 70.4% of local
cats were infected with type I FCoV. Infection with type
II FCoV in Taiwan (21.3%, 61/287) is higher than in
other countries, i.e., 4.4% in Switzerland and 10.1% and
2% in Japan in 1992 and 2007, respectively. The dense
population and close contact between cats and other an-
imals in Taiwan could be reasons contributing to the
higher rate of recombination between FCoVs and CCoVs
or other alphacoronaviruses, leading to a relatively high
type II FCoV infection rate. This relatively high antibody
titer against type II virus might also result from other
alphacoronavirus infection, as feline cells are susceptible
to infection with FCoV, CCoV, TGEV and HCoV-229E
[25] and given that seroconversion was observed in cats
experimentally infected with CCoV [26], TGEV [27] or
HCoV-229E [28].
In a prior study, a competitive ELISA was used to dis-
criminate the serotype of infection [11]. However, certain
sera could not be typed once inhibition reached 30-80%.In the present study, serotypes were determined by the
direct observation of a fluorescent signal specifically indi-
cating two types of recombinant protein, which decreased
the ambiguity. In another IFA study using type I or type II
FCoV-infected cells, 23% of cats displayed equal titers
against type I and II FCoV. The phenomenon was sug-
gested by the authors to result either from antibodies
against common antigenic epitopes in other structural
protein or from co-infection with the two viruses [10].
Our type-specific S protein-based IFA can avoid the shar-
ing of common antigenicity, and co-infection can be read-
ily identified.
This is the first report to correlate viral infection with
the specific antibody evoked. We compared the sero-
types and the genotypes of FCoV-infected animals. Most
type I FCoV-infected cats with FIP harbored anti-type I
FCoV antibodies, and three of them displayed antibodies
against both types of FCoV, indicating co-infection with
FCoV and/or other CoVs. Additionally, one cat with type
II FIP (FIP-24) displayed an antibody response to type I
and II FCoV simultaneously. This finding matches the
recombination theory that states that type II FCoV arises
from the mutation of type I FCoV. However, we found
that three cats with type II FIP possessed antibodies
solely against type II FCoV. Among those cats, FIP-23
(cat 11) was living in a shelter that had experienced a re-
cent FIP outbreak caused by type II FCoV [29]. The
presence of antibodies solely against type II FCoV in cat
FIP-23 provides an additional clue about the horizontal
transmission of type II FIP. In the case of cat FIP-22, se-
quencing analysis of the C-terminal one-third of the
viral genome indicated a virus bearing high resemblance
to CCoV, but not to FCoV. Combining the serological
and genetic findings, this FIP could have resulted from a
CCoV infection. Further genetic analysis regarding this
speculation is currently under investigation.
Among healthy cats with untypable FCoV, 84.6% were
found to have a type I FCoV infection. Although the
serotype of the antibodies detected did not always match
the virus present at the time of sampling, infection with
FCoVs, and especially with type I, is persistent and can
last for several years in a multicat environment [14,30].
Moreover, type I virus has been reported to be more
genetically diverse than type II virus in the genotyped re-
gion, and this diversity might hinder PCR amplification
[16]. Despite the better distinguishability, 8.3% of the
cats in the current study possessed anti-FCoV antibodies
that could not be serotyped. This issue could have been
due to the lower antibody titers against FCoV, or poly-
morphisms may exist in the target region in S protein.
FCoV antibody titers when accurately performed are
thought to be of some value in distinguishing enteric in-
fection from FIP. Cats with IFA titers ≥1:3200 are highly
suggestive of FIP [31]. In our study using the serotyping
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be titrated and the titer in some of our FIP cats reached
relatively high level as well (≥1:1600). Our recent study
revealed that the infection of serotype II FCoV corre-
lated significantly with the occurrence of FIP [16]. Also
horizontal transmission of a serotype II virus was clearly
demonstrated to responsible for a FIP outbreak [29].
Continuous survey of the antibodies against two sero-
type of FCoV, especially in the multi-cat environment
could help in identifying the invasion of any type II
FCoV hence isolating the animals to prevent future FIP
occurrence.
Conclusions
In conclusion, compared with the results of previous
studies, we present a relatively simple serotyping method
to discriminate between two types of FCoV infection.
Based on this method, type I FCoV was found to be pre-
dominant compared with type II in Taiwan. This survey
also provided clues supporting the evolution and hori-
zontal transmission of type II FIPV. The epidemiological
survey also provided valuable information for disease
control and vaccine development.
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